| Popis: |
ObjectiveTo explore the main active components of Hohgardi-9 and its mechanism treating in ALI.MethodsThrough searching the TCMSP database, we obtained the main components and action targets of Hohgardi-9, and the targets related to ALI were analyzed as the possible targets of Hohgardi-9. Then, the compound target network was constructed using Cytoscape software and obtained the key compounds of Hohgardi-9 acting on ALI. The blood entering components of Hohgardi-9 were analyzed by metabonomics. Using a string database to investigate the interaction between proteins of possible targets of Hohgardi-9, Gene Ontology (GO) function annotation and Tokyo Encyclopedia of the genome (KEGG) pathway enrichment analysis were carried out at the same time to predict its mechanism. Finally, the ALI rat model verified the pharmacodynamic effects and key targets of Huhgridi-9.ResultsThe network pharmacology and blood component analysis results showed that 27 potentially active components such as quercetin, herbacetin, izoteolin, and columbinetin acetate were the major functional components in Hohgardi-9. Those might act on NF kappa B signalling pathway, toll-like receptor signalling pathway, and TNF signalling pathway through key targets such as RELA (p65), TLR4, etc. In vivo experiments showed that Hohgardi-9 significantly improved lung tissue injury and pulmonary edema in ALI rats. At the same time, the Hohgardi-9 intervention could significantly reduce the mRNA expression levels of TRL4, TNFa, IL-1 β, and ICAM1 in ALI rats.ConclusionHohgardi-9 revealed ALI through the inhibiting inflammatory factor apoptosis-related gene expression. |
